(lp0
S"NewLink Genetics Corp. stock drops 28% on mid-stage results for melanoma drug MarketWatch - Apr 4, 2017 NewLink Genetics Corp. NLNK, +0.13% shares dropped as much as 27.7% in morning trade Tuesday after the company released interim results for a phase 2 trial for advanced melanoma.Why NewLink Genetics Shares Fell 10.3% Today - Motley FoolAnalysts defend NewLink's indoximod data as shares slump 19% - Seeking Alpha"
p1
aS'NewLink Genetics Unfairly Punished Seeking Alpha - Apr 6, 2017 The market punished NewLink Genetics  after presenting data on their indoleamine 2,3-dioxygenase  combination with Keytruda in advanced melanoma.'
p2
aS"NewLink Genetics Announces Presentation of Two Abstracts at AACR GlobeNewswire  - Mar 1, 2017 Clinical Trials Plenary Session: Abstract CT117 - Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma, to be presented during the Novel&nbsp;...NewLink Genetics'  CEO Charles Link on Q4 2016 Results - Earnings Call ... - Seeking Alpha"
p3
aS'NewLink Genetics Corp  Receives $31.20 Consensus Price Target from ... The Cerbat Gem - 13 hours ago NewLink Genetics Corp logo Shares of NewLink Genetics Corp  have received a consensus recommendation of Buy from the seven research firms that are covering the stock.Zacks: Analysts Anticipate NewLink Genetics Corp  Will Announce Earnings ... - Markets DailyAnalyst Target Price Look at NewLink Genetics Corporation (NASDAQ:NLNK ... - Davidson Register'
p4
aS"NewLink Genetics Corporation  Plunges 7.7% on April 07 Equities.com - Apr 7, 2017 NewLink Genetics Corporation  had a rough trading day for Friday April 07 as shares tumbled 7.7%, or a loss of $-1.35 per share, to close at $16.19.Analyst's Predictions on Nektar Therapeutics , NewLink Genetics ... - StockNewsJournalNewLink Genetics Corporation declined in the Previous Trading Session with the ... - Free Observer"
p5
aS'NewLink Genetics Has Many Near-Term Catalysts Seeking Alpha - Sep 27, 2016 NewLink Genetics  is a small biopharmaceutical company  developing novel immuno-oncology product candidates.'
p6
aS'NewLink Genetics: A Classic Value Catalyst Buy Seeking Alpha - Dec 29, 2016 Current information hints that IDO inhibitors have an important role to play in oncology and NewLink Genetics should be given more credit for its pipeline.'
p7
aS'TrovaGene and NewLink Genetics Find Investors Optimistic About Products Yahoo Finance - Mar 31, 2017 The surge in price came after Peter Lawson of SunTrust Robinson Humphrey upgraded the company from &quot;hold&quot; to &quot;buy&quot; and raised the price target to $30 from a previous target of $12, and expressed his view that NewLink is &quot;well positioned&quot; to become a&nbsp;...'
p8
aS'Unnoticed By The Street, Roche Updated NewLink Genetics IDO Partnership At ESMO Seeking Alpha - Nov 17, 2016 Roche declares on NLNK IDO &quot;We are taking it forward&quot; and outlines plan to extend IDO inhibition &quot;to a broader class of tumors&quot;.'
p9
aS'NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference ... Yahoo Finance - Apr 13, 2017 AMES, Iowa, April 13, 2017  -- NewLink Genetics Corporation , today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017.'
p10
a.